INVESTIGATOR-INITIATED CLINICAL TRIALS FOR NEW DRUGS IN JAPAN: CHALLENGES AND PERSPECTIVES

被引：0
|
作者：
Katsumata, N. [1 ]
机构：
[1] Musashi Kosugi Hosp Med Oncol, Nippon Med Sch, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [31] Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations
    Lingor, Paul
    Koch, Jan C.
    Statland, Jeffrey M.
    Hussain, Sumaira
    Hennecke, Christiane
    Wuu, Joanne
    Langbein, Thomas
    Ahmed, Raees
    Guenther, Rene
    Ilse, Benjamin
    Kassubek, Jan
    Kollewe, Katja
    Kuttler, Josua
    Leha, Andreas
    Lengenfeld, Teresa
    Meyer, Thomas
    Neuwirth, Christoph
    Tostmann, Ralf
    Benatar, Michael
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2021, 22 (5-6) : 419 - 425
  • [32] NIH MULTICENTER INVESTIGATOR-INITIATED TRIALS - AN ENDANGERED SPECIES
    MEINERT, CL
    CONTROLLED CLINICAL TRIALS, 1988, 9 (02): : 97 - 102
  • [33] Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer
    Tsai, Susan
    Evans, Douglas B.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (01) : 69 - 74
  • [34] Investigation of the Factors Affecting Risk-Based Quality Management of Investigator-Initiated Investigational New-Drug Trials for Unapproved Anticancer Drugs in Japan
    Sudo, Tomohisa
    Sato, Akihiro
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 589 - 596
  • [35] Investigation of the Factors Affecting Risk-Based Quality Management of Investigator-Initiated Investigational New-Drug Trials for Unapproved Anticancer Drugs in Japan
    Tomohisa Sudo
    Akihiro Sato
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 589 - 596
  • [36] Ohio CTSAs Implement a Reliant IRB Model for Investigator-Initiated Multicenter Clinical Trials
    Cola, Philip A.
    Reider, Carson
    Strassor, Jane E.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2013, 6 (03): : 176 - 178
  • [37] The consequences of good clinical practice for investigator-initiated research
    Swank, H. A.
    Morton, D. G.
    Meijer, D. W.
    Bemelman, W. A.
    COLORECTAL DISEASE, 2011, 13 (10) : 1190 - 1192
  • [38] The consequences of good clinical practice for investigator-initiated research
    Swank, H. A.
    Morton, D. G.
    Meijer, D. W.
    Bemelman, W. A.
    COLORECTAL DISEASE, 2012, 14 (01) : 119 - 121
  • [39] Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center
    Aldrich, Jeffrey
    Ekpo, Princess
    Rupji, Manali
    Switchenko, Jeffrey M.
    Torres, Mylin A.
    Kalinsky, Kevin
    Bhave, Manali A.
    CLINICAL BREAST CANCER, 2023, 23 (01) : 38 - 44
  • [40] Comparison of investigator-initiated and industry-initiated trials in Canada and other countries.
    Wong, Bryan
    North, Scott A.
    Ben Tran
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345